OR WAIT null SECS
© 2023 MJH Life Sciences™ and BioPharm International. All rights reserved.
Independent research performed at the University of St. Andrews in the UK has reportedly demonstrated the effectiveness of Alfacyte in-vitro against SARS-CoV-2.
According to an Oct. 6, 2020 press release, independent research performed at the University of St. Andrews in the United Kingdom has reportedly demonstrated the effectiveness of Alfacyte in-vitro against SARS-CoV-2.
Alfacyte, a unique synthetic Interferon from ILC Therapeutics, is claimed to be more effective at preventing the spread of SARS-CoV-2 in cell culture when compared with other commercially available Interferons. The research into the effectiveness of Alfacyte is being led by Dr. Catherine Adamson, a specialist in viral diseases at the University of St. Andrews.
“This [research] is a hugely exciting development and it demonstrates that there is a significant difference in the bioactivity of Interferon sub types against coronaviruses,” said Adamson in the press release. “These differences may have important therapeutic implications for COVID-19.”
“COVID-19 and other coronaviruses have spent a lot of evolutionary energy trying to protect themselves against the Interferon alpha because overcoming the innate immune system is their main concern,” added Prof. William Stimson, founder and chief scientific officer at ILC Therapeutics, in the press release. “Timing is everything and by delivering a powerful Interferon like Alfacyte to the airways using a nebulizer we hope to accelerate and support the innate immune defenses and prevent viral infection spreading and worsening.”
Further tests are being conducted on Alfacyte by ILC Therapeutics, which is hoping to proceed to clinical trials in 2021.
Source: ILC Therapeutics